Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials

Abstrakt

We have confirmed both the efficacy and safety of dasatinib in patients with CML in different stages when generally treated outside of clinical trials. Well-managed centralized care of patients with CML permits treatment event monitoring and composite endpoint analyses, such as FFS, TFFS or ATFS, which can reveal particular therapy status in a more detailed and realistic manner.

Klíčová slova

• high-dose imatinib
• cytogenetic responses
• randomized phase-2
• resistant
• therapy
• inhibition
• survival
• abl